These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 27373139

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):1. PubMed ID: 31910850
    [Abstract] [Full Text] [Related]

  • 23. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A.
    Int J Cardiol; 2016 Jun 01; 212():29-36. PubMed ID: 27017118
    [Abstract] [Full Text] [Related]

  • 24. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A, Node K.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):85. PubMed ID: 29895290
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH, Barry AR, Koshman SL.
    Am J Health Syst Pharm; 2017 Jul 01; 74(13):970-976. PubMed ID: 28483748
    [Abstract] [Full Text] [Related]

  • 26. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR, TECOS Executive Committee.
    Diabetes Obes Metab; 2015 Apr 01; 17(4):395-402. PubMed ID: 25600421
    [Abstract] [Full Text] [Related]

  • 27. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 28. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S, Baker WL, White WB.
    Curr Cardiol Rep; 2014 Nov 02; 16(11):541. PubMed ID: 25303895
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B.
    Lancet Diabetes Endocrinol; 2016 May 02; 4(5):411-9. PubMed ID: 27009625
    [Abstract] [Full Text] [Related]

  • 31. Cardiovascular Protection with Anti-hyperglycemic Agents.
    Deedwania P, Acharya T.
    Am J Cardiovasc Drugs; 2019 Jun 02; 19(3):249-257. PubMed ID: 30767126
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Gliptins, cardiovascular safety and congestive heart failure: state of the art after TECOS].
    Scheen AJ.
    Rev Med Suisse; 2015 Aug 26; 11(483):1526-31. PubMed ID: 26502578
    [Abstract] [Full Text] [Related]

  • 36. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK, Singh R.
    Expert Rev Clin Pharmacol; 2017 Apr 26; 10(4):429-442. PubMed ID: 28121469
    [Abstract] [Full Text] [Related]

  • 37. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ.
    Diab Vasc Dis Res; 2016 Nov 26; 13(6):382-383. PubMed ID: 27543327
    [No Abstract] [Full Text] [Related]

  • 38. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J, Sands M, Burciu C, Reaven P.
    Diab Vasc Dis Res; 2015 May 01; 12(3):154-63. PubMed ID: 25852133
    [Abstract] [Full Text] [Related]

  • 40. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 01; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.